Recalls & Warnings December 08, 2017 Limbrel Capsules for Osteoarthritis Linked With Potentially Life-Threatening Health Risk, FDA Warns On December 4, 2017, the FDA urged consumers not to take Limbrel (Primus Pharmaceuticals), a capsule marketed to manage the metabolic processes associated with osteoarthritis, because it has been associated with serious adverse events, including drug-induced liver injury and a lung
Pricing differences reflect manufacturing scale, regulatory oversight, and distribution controls
Other factors, including patient age, gender, body mass index (BMI), and hepatitis C infection, further exacerbate the risk of PTDM. Current management of PTDM remains a challenge, often requiring adjustment immunosuppressant regimens and promoting lifestyle changes
Best to be taken on a full stomach